Arcturus Therapeutics Holdings Inc. (ARCT) reported a wider-than-expected loss for the fourth quarter of 2024, with earnings per share (EPS) of -$1.11, missing the forecast of -$0.19. The company’s revenue also fell short of expectations, coming in at $22.8 million against the forecasted $63.22 million. Following the earnings release, Arcturus’ stock fell 6.95% in after-hours trading, with shares priced at $14.86, nearing its 52-week low of $14.30. According to InvestingPro data, the stock has experienced significant volatility, with a beta of 2.96, and has declined over 57% in the past year.
Key Takeaways
- Arcturus reported a significant EPS miss, with a loss of $1.11 per share against a forecast of -$0.19.
- Quarterly revenue decreased to $22.8 million, falling short of the expected $63.22 million.
- The stock dropped 6.95% in after-hours trading, reflecting investor disappointment.
- The company maintains a strong cash position with $293.9 million in cash and equivalents.
- Key product developments include the approval of CoStave, a self-amplifying mRNA COVID-19 vaccine in the EU.
Company Performance
Arcturus Therapeutics experienced a challenging fourth quarter, with both revenue and earnings missing analyst expectations. The company’s annual revenue declined to $152.3 million, down $14.5 million from the previous year. Despite these setbacks, Arcturus continues to focus on its innovative self-amplifying mRNA platform, which it sees as a competitive advantage in the biotechnology sector. InvestingPro analysis indicates the stock is currently undervalued, with 7 additional exclusive ProTips available to subscribers. The company maintains a "GOOD" overall Financial Health score of 2.76, suggesting resilience despite current challenges.
Financial Highlights
- Revenue: $22.8 million in Q4, down $8.1 million from the same quarter last year.
- Annual Revenue: $152.3 million, a decrease of $14.5 million from 2023.
- Net Loss: $30 million for Q4, translating to a loss of $1.11 per diluted share.
- Cash and Equivalents: $293.9 million as of December 31, 2024, with InvestingPro data showing a strong current ratio of 4.76 and liquid assets exceeding short-term obligations. The company holds more cash than debt on its balance sheet, with total debt of just $29.42 million.
Earnings vs. Forecast
Arcturus reported an EPS of -$1.11, significantly below the forecasted -$0.19, resulting in a negative surprise. This miss is notable compared to previous quarters, where the company had managed to stay closer to analyst expectations. Revenue also fell short of the anticipated $63.22 million, coming in at $22.8 million.
Market Reaction
Following the earnings announcement, Arcturus’ stock declined by 6.95% in after-hours trading, with shares priced at $14.86. This drop positions the stock close to its 52-week low of $14.30, reflecting investor concerns over the company’s financial performance and future outlook.
Outlook & Guidance
Looking ahead, Arcturus has provided revised guidance for 2025, with projected EPS losses of -$0.3 for Q1 and -$0.09 for Q2. The company anticipates revenue of $62.5 million and $70.3 million for these quarters, respectively. Arcturus remains focused on expanding its therapeutic and vaccine pipelines, with interim data for key programs expected in 2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.